Close Menu

non-small cell lung cancer

Abbott and GSK will develop and commercialize a PCR test for the MAGE-A3 biomarker using Abbott's m2000 automated real-time PCR system.

Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that the company said can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens.

Using gene expression data on nearly 800 non-small lung cancer samples from four previously published studies, a team of Duke University researchers has identified age- and sex-specific pathways linked to NSCLC recurrence risk.

Rosetta plans to use the proceeds for general corporate purposes and to support the development of its microRNA-based diagnostic pipeline.

The microRNA-based molecular diagnostics developer plans to use earnings from the sale of securities for a range of corporate purposes.

A new study from Johns Hopkins and Rosetta researchers finds the miRview NSCLC test to be effective.

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

Biodesix offers to help pay for the cost of the test for those patients whose doctors have determined they need it, but who don't have adequate insurance coverage.

The proceeds will support commercialization of the company's gene expression-based assay for early-stage non-small-cell lung cancer.

The two companies announced plans to develop a companion diagnostic to predict whether non-squamous non-small cell lung cancer patients can benefit from combination treatment with Alimta and cisplatin based on the thymidylate synthase biomarker.

Pages

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.